|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia resulting from the reduced expression of erythropoietin (EPO) is a common complication of patients with chronic kidney diseases (CKD).
|
28625716 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that impaired production of Epo may be a direct effect of HIV-1 infection possibly contributing to anemia in AIDS.
|
8390370 |
1993 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Accelerating Epo production in hepatocytes is one plausible therapeutic strategy for treating anemia caused by kidney diseases.
|
26012551 |
2015 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy.
|
15467711 |
2005 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated anemia.
|
10326023 |
1998 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Proinflammatory cytokine, mainly IL-6, which are released by both tumor and immune cells, play a pivotal action in CRA etiopathogenesis: they promote alterations in erythroid progenitor proliferation, erythropoietin (EPO) production, survival of circulating erythrocytes, iron balance, redox status, and energy metabolism, all of which can lead to anemia.
|
30294279 |
2018 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hypoxia-regulated system of Epo gene expression constructed by fusing Epo to the HRE/CMV promoter and delivered by plasmid intramuscular injection may provide a long-term and stable Epo expression and secretion in vivo to correct the anemia in adenine-induced uremic rats.
|
22990115 |
2012 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus.
|
6095306 |
1984 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The anemia of the newborn induces erythropoietin expression in the developing mouse retina.
|
20463184 |
2010 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that combination Fe + EPO therapy is effective in partially reversing ICU anemia when administered after the phase of acute inflammation.
|
28452907 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia.
|
30097240 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
|
30544934 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
|
17559739 |
2007 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The therapy for anemia evaluated in the most studies was erythropoietin-stimulating agents (77.7% of studies).
|
30100259 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Iron deficiency is a common etiology of anemia that causes suboptimal response to erythropoietin therapy in hemodialysis (HD) patients.
|
31679114 |
2020 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD).
|
29296077 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epoetin-α reduced RBC transfusions and increased the time-to-first-transfusion compared with placebo.Thus, epoetin-α significantly improved anemia outcomes in low-risk MDS.
|
29895954 |
2018 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The effectiveness of biosimilar epoetin alfa (Binocrit<sup>®</sup>, Sandoz) to correct anemia in lower-risk MDS patients has also been demonstrated in a retrospective, single-center, observational study.
|
31005849 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin (Epo) supplementation is one of the methods for treating anemia.
|
27903235 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (EPO) has been used to treat anemia of cancer patients, because it stimulates erythropoiesis.
|
28247960 |
2017 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Despite specific therapy now available for anemia in CKD, clinical data accumulated in the last 2 decades suggests that there is a continued need for RBCT, which, we surmise, is due to underutilization of Erythropoietin Stimulating Agents (ESA) or clinical settings such as active bleed, bone marrow resistance such as myelofibrosis or infections where ESAs are ineffective.
|
31782127 |
2019 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The 5'-flanking region of the human erythropoietin (Epo) gene contains a 0.14-kb sequence that is conserved in the Epo gene from mouse and located within a promoter that is activated under hypoxic conditions such as anemia.
|
8486613 |
1993 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
This plasmid-based, antiprogestin-inducible EPO/GeneSwitch system has the potential to be a convenient, long-lasting and effective gene-based therapy for the treatment of anemia.
|
14668002 |
2003 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment with erythropoietin (Epo) alone or in combination with granulocyte colony-stimulating factor (G-CSF) may significantly improve anemia and reduce bone marrow apoptosis.
|
16645228 |
2006 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Several studies on the use of erythropoietin (Epo) to treat anaemia in patients undergoing cancer treatment have shown adverse effects on tumour control and survival.
|
25182342 |
2014 |